Health professionals, community groups, academics and policy makers can now access latest, evidence-based recommendations on the management of hepatitis c among people who inject drugs.
Released as part of a Special Issue on Expanding Access to Prevention, Care and Treatment for Hepatitis C Virus Infection Among People Who Inject Drugs in the International Journal of Drug Policy, the recommendations provide invaluable guidance through the rapidly changing HCV therapy landscape, and integrate this with prevention and care.
These recommendations are founded on latest evidence, and provide guidance on a range of issues from adherence and reinfection, to cost-effectiveness and integration of healthcare delivery services. They in line with the methodologies used by international guidelines from AASLD and IDSA (AASLD/IDSA, 2015).
Read the media release and access the Recommendations.